Tech Company Financing Transactions
IRX Therapeutics Funding Round
IRX Therapeutics, operating out of New York, secured $20 million in funding from private investors.
Transaction Overview
Company Name
Announced On
8/30/2017
Transaction Type
Venture Equity
Amount
$19,993,435
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 98 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
654 Madison Ave. 1601
New York, NY 10065
USA
New York, NY 10065
USA
Phone
Website
Email Address
Not Recorded
Overview
IRX Therapeutics' mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Leuchtenberger
Chief Financial Officer
Curtis Robb
Chief Operating Officer
Monil Shah
Chief Scientific Officer
Neil Berinstein
VP - Regulatory Affairs
Zygmund Roth
Browse more venture capital transactions:
Prev: 8/30/2017: Lookingglass Cyber Solutions venture capital transaction
Next: 8/30/2017: Vulog venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs